Alpha 2.0

» Articles » PMID: 25893411

Photoimmunotherapy Inhibits Tumor Recurrence After Surgical Resection on a Pancreatic Cancer Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model

Overview

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2015 Apr 21

PMID 25893411

Citations 15

Authors

Authors

Yukihiko Hiroshima

Ali Maawy

Yong Zhang

Miguel Garcia Guzman

Roger Heim

Lew Makings

George A Luiken

Hisataka Kobayashi

Kuniya Tanaka

Itaru Endo

Robert M Hoffman

Michael Bouvet

Affiliations

Affiliations

Soon will be listed here.

Abstract

Background: Photoimmunotherapy (PIT) uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, to induce tumor necrosis after irradiation with NIR light to kill cancer cells, such as those that remain after surgery. The purpose of the present study was to sterilize the surgical bed after pancreatic cancer resection with PIT in carcinoembryonic antigen (CEA)-expressing, patient-derived, orthotopic xenograft (PDOX) nude mouse models.

Methods: After confirmation of tumor engraftment, mice were randomized to two groups: bright light surgery (BLS)-only and BLS + PIT. Each treatment arm consisted of seven tumor-bearing mice. BLS was performed under standard bright-field with an MVX10 long-working distance, high-magnification microscope on all mice. For BLS + PIT, anti-CEA antibody conjugated with IR700 (anti-CEA-IR700) (50 µg) was injected intravenously in all mice 24 h before surgery. After the surgery, the resection bed was then irradiated with a red-light-emitting diode at 690 ± 5 nm with a power density of 150 mW/cm(2).

Results: Anti-CEA-IR700 labelled and illuminated the pancreatic cancer PDOX. Minimal residual cancer of the PDOX was detected by fluorescence after BLS. The local recurrence rate was 85.7 % for BLS-only and 28.6 % for BLS + PIT-treated mice (p = 0.05). The average recurrent tumor weight was 1149.0 ± 794.6 mg for BLS-only and 210.8 ± 336.9 mg for BLS + PIT-treated mice (p = 0.015).

Conclusion: Anti-CEA-IR700 was able to label and illuminate a pancreatic cancer PDOX nude mouse model sufficiently for PIT. PIT reduced recurrence by eliminating remaining residual cancer cells after BLS.

Citing Articles

Near Infrared Photoimmunotherapy: A Review of Recent Progress and Their Target Molecules for Cancer Therapy.

Mohiuddin T, Zhang C, Sheng W, Al-Rawe M, Zeppernick F, Meinhold-Heerlein I Int J Mol Sci. 2023; 24(3).

PMID: 36768976 PMC: 9916513. DOI: 10.3390/ijms24032655.

Lectin-based phototherapy targeting cell surface glycans for pancreatic cancer.

Kuroda Y, Oda T, Shimomura O, Hashimoto S, Akashi Y, Miyazaki Y Int J Cancer. 2022; 152(7):1425-1437.

PMID: 36412556 PMC: 10107464. DOI: 10.1002/ijc.34362.

Near infrared photoimmunotherapy of cancer; possible clinical applications.

Wakiyama H, Kato T, Furusawa A, Choyke P, Kobayashi H Nanophotonics. 2022; 10(12):3135-3151.

PMID: 36405499 PMC: 9646249. DOI: 10.1515/nanoph-2021-0119.

Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond.

Wei D, Qi J, Hamblin M, Wen X, Jiang X, Yang H Theranostics. 2022; 12(16):7108-7131.

PMID: 36276636 PMC: 9576624. DOI: 10.7150/thno.74820.

Near-Infrared Photoimmunotherapy for Thoracic Cancers: A Translational Perspective.

Matsuoka K, Yamada M, Sato M, Sato K Biomedicines. 2022; 10(7).

PMID: 35884975 PMC: 9312913. DOI: 10.3390/biomedicines10071662.

References

1.

Yamaguchi K, Enjoji M, Tsuneyoshi M . Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol. 1991; 47(3):148-54. DOI: 10.1002/jso.2930470303. View

2.

Hoffman R . Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs. 2000; 17(4):343-59. DOI: 10.1023/a:1006326203858. View

3.

Mitsunaga M, Ogawa M, Kosaka N, Rosenblum L, Choyke P, Kobayashi H . Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011; 17(12):1685-91. PMC: 3233641. DOI: 10.1038/nm.2554. View

4.

Fu X, Le P, Hoffman R . A metastatic orthotopic-transplant nude-mouse model of human patient breast cancer. Anticancer Res. 1993; 13(4):901-4. View

5.

Furukawa T, Kubota T, Watanabe M, Kitajima M, Hoffman R . A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. Cancer Res. 1993; 53(13):3070-2. View

6.

Yamauchi K, Yang M, Jiang P, Xu M, Yamamoto N, Tsuchiya H . Development of real-time subcellular dynamic multicolor imaging of cancer-cell trafficking in live mice with a variable-magnification whole-mouse imaging system. Cancer Res. 2006; 66(8):4208-14. DOI: 10.1158/0008-5472.CAN-05-3927. View

7.

Fu X, Besterman J, Monosov A, Hoffman R . Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci U S A. 1991; 88(20):9345-9. PMC: 52711. DOI: 10.1073/pnas.88.20.9345. View

8.

Wang X, Fu X, Hoffman R . A new patient-like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice. Int J Cancer. 1992; 51(6):992-5. DOI: 10.1002/ijc.2910510626. View

9.

Togo S, Shimada H, Kubota T, Moossa A, Hoffman R . Host organ specifically determines cancer progression. Cancer Res. 1995; 55(3):681-4. View

10.

Mitsunaga M, Nakajima T, Sano K, Choyke P, Kobayashi H . Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconjug Chem. 2012; 23(3):604-9. PMC: 3401044. DOI: 10.1021/bc200648m. View

11.

Maawy A, Hiroshima Y, Zhang Y, Heim R, Makings L, Garcia-Guzman M . Near infra-red photoimmunotherapy with anti-CEA-IR700 results in extensive tumor lysis and a significant decrease in tumor burden in orthotopic mouse models of pancreatic cancer. PLoS One. 2015; 10(3):e0121989. PMC: 4370703. DOI: 10.1371/journal.pone.0121989. View

12.

Xu C, Sun Y, Wang Y, Yan Y, Shi Z, Chen L . CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer. Cancer Lett. 2012; 319(2):154-163. DOI: 10.1016/j.canlet.2012.01.009. View

13.

Hiroshima Y, Zhang Y, Zhang N, Maawy A, Mii S, Yamamoto M . Establishment of a patient-derived orthotopic Xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. PLoS One. 2015; 10(2):e0117417. PMC: 4331082. DOI: 10.1371/journal.pone.0117417. View

14.

Kato K, Yamada S, Sugimoto H, Kanazumi N, Nomoto S, Takeda S . Prognostic factors for survival after extended pancreatectomy for pancreatic head cancer: influence of resection margin status on survival. Pancreas. 2009; 38(6):605-12. DOI: 10.1097/MPA.0b013e3181a4891d. View

15.

Fu X, Hoffman R . Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res. 1993; 13(2):283-6. View

16.

Fu X, Guadagni F, Hoffman R . A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A. 1992; 89(12):5645-9. PMC: 49349. DOI: 10.1073/pnas.89.12.5645. View

17.

Astoul P, Colt H, Wang X, Hoffman R . Metastatic human pleural ovarian cancer model constructed by orthotopic implantation of fresh histologically-intact patient carcinoma in nude mice. Anticancer Res. 1993; 13(6A):1999-2002. View